Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine - Takeaways - MDSpire

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine

  • By

  • Spyros Chalkias

  • Antionette Pragalos

  • Adebayo Akinsola

  • Gary Berman

  • Madhavi Ampajwala

  • Jay Meyer

  • Lorraine Schoch

  • Wen Zhou

  • Yamuna D Paila

  • Weiping Deng

  • Jing Feng

  • Elizabeth de Windt

  • Darin Edwards

  • Jacqueline Miller

  • Rituparna Das

  • January 10, 2025

  • 0 min

Share

  • 1

    mRNA-1283 is an investigational COVID-19 vaccine targeting the receptor-binding and N-terminal domains of the SARS-CoV-2 spike protein.

  • 2

    A phase 2a study showed that mRNA-1283 was well tolerated and elicited higher neutralizing antibody responses than the original mRNA-1273 vaccine.

  • 3

    The study included 340 participants in part A and 200 in part B, evaluating various formulations of mRNA-1283 against mRNA-1273.

  • 4

    mRNA-1283.529, a monovalent vaccine for Omicron BA.1, also demonstrated increased neutralizing antibody responses at day 29.

  • 5

    Antibody responses from mRNA-1283 remained detectable for a year post-vaccination, indicating prolonged immunogenicity.

Original Source(s)

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine

  • by Spyros Chalkias, Antionette Pragalos, Adebayo Akinsola, Gary Berman, Madhavi Ampajwala, Jay Meyer, Lorraine Schoch, Wen Zhou, Yamuna D Paila, Weiping Deng, Jing Feng, Elizabeth de Windt, Darin Edwards, Jacqueline Miller, Rituparna Das

  • January 10, 2025

Related Content

“Who’s on Backup?”—Exploring Internal Medicine Residency Backup Coverage Systems: Findings from a National Survey

Long COVID as a network disorder: a mechanism-anchored framework for biological stratification and therapeutic targeting

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.